Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Chromadex Corp CS
(NQ:
CDXC
)
3.300
-0.180 (-5.17%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Chromadex Corp CS
< Previous
1
2
3
Next >
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
March 08, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023
March 06, 2023
From
ChromaDex Corpor
Via
Business Wire
ChromaDex to Report Fourth Quarter and Fiscal Year 2022 Financial Results on Wednesday, March 8, 2023
February 27, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Issuance of New U.S. Patent on Dihydronicotinamide Riboside (NRH) and Dihydronicotinic Acid Riboside (NARH), Further Solidifying ChromaDex as the Leader in the Nicotinamide Adenine Dinucleotide (NAD+) Precursor Space
February 22, 2023
From
ChromaDex Corporation
Via
Business Wire
A Letter from the ChromaDex Chief Executive Officer
February 21, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Shares Promising Findings from a Clinical Study Showcasing Combined Metabolic Activators (CMAs), Featuring Nicotinamide Riboside (NR), Improved Cognitive Functions in Alzheimer's Disease (AD) Patients
January 31, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Shares Promising Findings from First-Of-Its Kind Clinical Study to Demonstrate Oral Nicotinamide Riboside (NR) Supplementation Increases Muscle Mitochondrial Biogenesis
January 17, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Appoints Leading Aging and Neurodegenerative Disease Researcher, Dr. Vilhelm Bohr, to its Scientific Advisory Board (SAB)
January 12, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Named Brianna Gerber Chief Financial Officer
January 05, 2023
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers
December 27, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Reports FDA’s Conclusion that Nicotinamide Mononucleotide (NMN) May Not Be Sold or Marketed as a Dietary Supplement in the United States
November 11, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
November 02, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022
October 26, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex and Nestlé Health Science Announce New Niagen® Commercial Supply Agreement and $5 Million Investment
October 11, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex’s Tru Niagen® Won the "Most Popular Brand of the Year Award" at China International Natural Health & Nutrition Expo’s (NHNE) Prestigious Nutrition Planet Awards
October 24, 2022
From
ChromaDex Corporation
Via
Business Wire
Sinopharm Xingsha to Introduce ChromaDex’s Tru Niagen® at Major Mainland China Trade Show, China International Natural Health & Nutrition Expo (NHNE)
September 19, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Shares Promising Findings from Clinical Study Showcasing the Safety and Tolerability of Nicotinamide Riboside (NR) in Heart Failure With Reduced Ejection Fraction
October 04, 2022
From
ChromaDex Corporation
Via
Business Wire
Thorne Research, Inc. Loses Patent Challenge Decision, Upholding ChromaDex’s Intellectual Property Held Under Exclusive License From Dartmouth College
August 15, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Finalizes Commercial Joint-Venture in Asia and Announces $3.1 Million Private Placement of Common Stock
October 03, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
August 10, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
August 02, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Partnership with MyPharma2Go Corporation for Cross-Border Sales of Tru Niagen® and Tru Niagen® PRO into Brazil
September 01, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex To Host Key Opinion Leader Webinar on the Transforming Benefits of Nicotinamide Riboside (NR)
July 07, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Present at American Society for Nutrition (ASN), International Society of Sports Nutrition (ISSN), and Federation of American Societies for Experimental Biology (FASEB)
June 15, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Present at the Oppenheimer’s 22nd Annual Consumer Growth and E-Commerce Conference
June 07, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Partners with Juvenis for Cross-Border Sales of Tru Niagen® into South Korea
June 02, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Signs Sinopharm Xingsha Agreement to Accelerate Cross-Border Sales of Tru Niagen® into Mainland China
June 10, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex to Present at the LD Micro Invitational
June 01, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Announces Agreement to Launch Commercial Joint Venture in Mainland China
May 19, 2022
From
ChromaDex Corporation
Via
Business Wire
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®
May 17, 2022
From
ChromaDex Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.